

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Michele Baccarani, Giuseppe Saglio, John Goldman, Andreas Hochhaus, Bengt Simonsson, Frederick Appelbaum, Jane Apperley, Francisco Cervantes, Jorge Cortes, Michael Deininger, Alois Gratwohl, François Guilhot, Mary Horowitz, Timothy Hughes, Hagop Kantarjian, Richard Larson, Dietger Niederwieser, Richard Silver, and Rudiger Hehlmann

The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML). Although experience is too limited to permit evidence-based evaluation of survival, the available data fully justify critical reassessment of CML management. The panel therefore reviewed treatment of CML since 1998. It confirmed the value of IM (400 mg/day) and of conventional allogeneic hematopoietic stem cell transplantation (alloHSCT). It recommended that the preferred initial treatment for most patients

newly diagnosed in chronic phase should now be 400 mg IM daily. A dose increase of IM, alloHSCT, or investigational treatments were recommended in case of failure, and could be considered in case of suboptimal response. Failure was defined at 3 months (no hematologic response [HR]), 6 months (incomplete HR or no cytogenetic response [CgR]), 12 months (less than partial CgR [Philadelphia chromosome-positive (Ph⁺) > 35%]), 18 months (less than complete CgR), and in case of HR or CgR loss, or appearance

of highly IM-resistant *BCR-ABL* mutations. Suboptimal response was defined at 3 months (incomplete HR), 6 months (less than partial CgR), 12 months (less than complete CgR), 18 months (less than major molecular response [MMoIR]), and, in case of MMoIR loss, other mutations or other chromosomal abnormalities. The importance of regular monitoring at experienced centers was highlighted. (Blood. 2006;108:1809-1820)

© 2006 by The American Society of Hematology

Introduction

After the initial descriptions of chronic myeloid leukemia (CML) more than 150 years ago, little meaningful progress was made in its treatment for more than a century. Radiation therapy and busulfan contributed more to improving quality of life than to prolonging survival. Survival prolongation was first achieved with hydroxyurea (HU), much more with allogeneic hematopoietic stem cell transplantation (alloHSCT) and, later, in a minority of patients, with recombinant interferon-alpha (rIFN α).¹ Understanding the pathogenesis of the disease began with the discovery of the Philadelphia (Ph) chromosome followed by appreciation of its molecular counterpart, the *BCR-ABL* fusion gene.^{2,3} Recognition of the tyrosine kinase (TK) activity of the Bcr-Abl proteins led to the discovery of a new series of compounds targeted against *BCR-ABL*-encoded proteins, which inhibited the TK activity, thus aborting the signals controlling the leukemic phenotype.⁴ One of the TK inhibitors, imatinib mesylate (IM), was found to have a high and relatively specific biochemical activity and an acceptable pharmacokinetic and

toxicity profile, and was thus rapidly introduced into clinical practice.⁵⁻⁷ This resulted in a revolutionary step in the management of CML and by extension a shift in paradigm for the management of cancer in general.

The most recent comprehensive analysis of CML treatment was an evidence-based guideline developed in 1998 by an expert panel convened by the American Society of Hematology (ASH) covering conventional chemotherapy, rIFN α , and alloHSCT.⁸ TK inhibitors were not considered at that time but were subsequently the subjects of editorials and preliminary reviews.^{7,9-14} Although it is premature at this time to perform an evidence-based analysis of the effects of IM, the implications and consequences of the introduction of TK inhibitors are so important that it is not too early to review the available data and to discuss how the treatment of CML could be managed and further progress could be pursued based upon expert opinion. Therefore, the European LeukemiaNet appointed a panel of experts to review the current situation. This report constitutes its opinion.

From the Department of Hematology/Oncology "L. and A. Seràgnoli," University of Bologna, Italy; Department of Clinical and Biological Sciences, University of Turin at Orbassano, Turin, Italy; Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Faculty of Clinical Medicine Mannheim, University of Heidelberg, Mannheim, Germany; Department of Hematology, University Hospital, Uppsala, Sweden; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Hematology, Hammersmith Hospital, London, United Kingdom; Hematology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain; Department of Leukemia, M. D. Anderson Cancer Center, Houston, TX; Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, Portland; Department of Hematology, University Hospital, Basel, Switzerland; Department of Oncology, Hematology and Cell Therapy, Medical Oncology, Equipe d'accueil (EA) 3805, and Clinical Research Centre, Centre Hospitalier et Universitaire (CHU) La Milétrie, Poitiers, France; Centre for International Blood and Marrow

Transplant Research, Medical College of Wisconsin, Milwaukee; Institute of Medical and Veterinary Science, Adelaide, New South Wales, Australia; Department of Medicine and Cancer Research Center, University of Chicago, IL; Department of Hematology and Oncology, University of Leipzig, Germany; and New York Presbyterian-Weill Cornell Medical Center, New York, NY.

Submitted February 24, 2006; accepted May 2, 2006. Prepublished online as *Blood* First Edition Paper, May 18, 2006; DOI 10.1182/blood-2006-02-005686.

A note regarding the members of the panel identified in the title appears in "Appendix."

Supported by the European Union, Sixth Framework Programme, contract no. LSHC-CT-2004-503216 (European LeukemiaNet).

Reprints: Michele Baccarani, Department of Hematology-Oncology "L. and A. Seràgnoli," S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy; e-mail: baccarani@med.unibo.it.

© 2006 by The American Society of Hematology

Methods

Panel composition

The panel included 19 members with recognized clinical and research expertise in CML, of whom 10 came from the European Union countries (France, Germany, Italy, Spain, Sweden, and the United Kingdom), 1 from Switzerland, 7 from the United States, and 1 from Australia.

Scope of the review

The first step was to perform a comprehensive and critical review of the literature after 1998 (the date of the last ASH analysis). A computerized literature search of the Medline database was conducted in April 2005 and updated in November 2005. Relevant abstracts presented at the 2004 and 2005 meetings of ASH, the American Society of Clinical Oncology, the European Group for Blood and Marrow Transplantation (EBMT), the European Hematology Association, and the International Society for Experimental Hematology were also reviewed. Thereafter, the panel met several times to discuss definition, evaluation, and monitoring of the responses, as well as treatment policy. It was agreed that discussion and proposals should be limited to early chronic-phase (ECP) patients not only because the treatment of CML patients in a more advanced phase is less amenable to generalizations, but also to focus on the importance of a first-line treatment strategy, late therapeutic interventions being generally less effective.

Definitions

The criteria that we have used to distinguish CP from accelerated phase (AP) are those that have been used in the most recent treatment reports.¹⁵⁻²² These criteria are listed in Table 1, together with World Health Organization (WHO) criteria, which differs slightly.²³ The relative risk (RR) of progression and death in ECP patients may be calculated by using either the Sokal²⁴ or the Hasford²⁵ formulations (Table 2).

Summary and update of rIFN α

The superiority of rIFN α -based regimens over conventional chemotherapy was reported previously in the ASH analysis⁸ and was confirmed in a subsequent study.²⁶ A trial of rIFN α versus a combination of rIFN α and low-dose arabinosyl cytosine (LDAC)²⁷ partially confirmed an earlier study²⁸ reporting that the cytogenetic response (CgR) rate was higher with the combination, but that overall survival did not differ. A study testing 3 MIU of rIFN α 3 times a week versus 5 MIU/square meters body surface/day

indicated that the low dose was as effective and better tolerated than the high dose.²⁹ The last updates of the major rIFN α studies reported a 9- or 10-year overall survival (OS) ranging from 27% to 53%.³⁰ In 1 study of 317 patients who had achieved a complete CgR (CCgR), 50% were still in CCgR and 70% were alive after 10 years, with a significant difference in OS between low and high Sokal risk patients (10-year OS, 90% vs 40%).³¹ Residual leukemia was detectable at the molecular level in almost all these patients. Several studies have provided some insights into the biologic and molecular bases of the therapeutic effects of rIFN α ,³⁰ but there have been no new or updated clinical studies.

Summary and update of allogeneic and autologous HSCT

The ASH panel reported that about 50% of the patients who received alloHSCT in first CP from a matched-related donor remained alive and leukemia-free after 5 years.⁸ Several subsequent reports confirmed the data and extended the follow-up to 10 years, with an OS of 60% and an event-free survival (EFS) of 50%,^{32,33} and to 15 years, with an OS of 47%³⁴ and 52%.³⁵ In a meta-analysis of 3 randomized studies of 316 patients in CP, 10-year survival estimates were 63% and 65%.³⁶ The Center for International Blood and Marrow Transplant Research (CIBMTR) reported on 4513 patients, with a median age of 35 years, who received transplants between 1978 and 1997.³⁷ OS at 18 years was 50% for 3372 first CP patients and 20% for 1141 non-first CP patients. The cumulative incidence of relapse at 18 years was 25% for CP patients and 37% for the others. Relapses were seen up to 21 years after treatment. The longest follow-up of patients who received transplants from a matched-related donor is that reported by the EBMT on 2628 patients given transplants between 1980 and 1990.³⁸ OS at 20 years was 34% for all patients, 41% for patients who received transplants in first CP from a human leukocyte antigen (HLA)-identical sibling, and 49% for those who had an EBMT risk score of 0-1. In children, 10-year OS estimates were reported to be 65% to 70%.³⁹

An EBMT survey analyzed 3142 patients submitted to conventional alloHSCT in any phase of CML and from any donor.⁴⁰ This analysis led to the formulation of a prognostic score subsequently validated by 2 other analyses (Tables 3 and 4).^{41,42} Depending on the risk score, survival ranged from 72% to 11% in all patients and

Table 1. List of the criteria that have been proposed by the WHO²³ and of the criteria that have been used in most recent studies and in this review, for defining AP

WHO criteria ²³	Other criteria, including this report ¹⁵⁻²²
Blast cells in blood or bone marrow 10%-19%	Blast cells in blood or bone marrow 15%-29%; blast cells plus promyelocytes in blood or bone marrow more than 30%, with blast cells less than 30%
Basophils in blood 20% or more	Basophils in blood 20% or more
Persistent thrombocytopenia (platelet count less than $100 \times 10^9/L$) unrelated to therapy	Persistent thrombocytopenia (platelet count less than $100 \times 10^9/L$) unrelated to therapy
Thrombocytosis (platelet count greater than $1000 \times 10^9/L$) unresponsive to therapy	Not included
Increasing spleen size and increasing WBC count unresponsive to therapy	Not included
Cytogenetic evidence of clonal evolution (the appearance of additional genetic abnormalities that were not present at the time of diagnosis)	Not included

The definition of CP implies that none of these criteria are met. For the definition of blast crisis (BC), the WHO-recommended criteria are the percentage of blast cells in blood or bone marrow ($\geq 20\%$), extramedullary blast proliferation, or large foci or clusters of blasts in the bone marrow biopsy.²³ In recent treatment reports¹⁵⁻²² and in this review, the criteria for BC were limited to the percent of blast cells in peripheral blood or bone marrow ($\geq 30\%$, rather than $\geq 20\%$ as for WHO), or extramedullary blast involvement. It should be noticed that the introduction of new treatments could change the boundaries between CP, AP, and BC, and modify to some extent the classic subdivision of CML into 3 phases.

Table 2. Calculation of disease RR

	Calculation by Sokal et al ²⁴	Calculation by Hasford et al ²⁵
Age	0.116 × (age – 43.4)	0.666 when age ≥ 50 y
Spleen*	0.0345 × (spleen – 7.51)	0.042 × spleen
Platelet count, × 10 ⁹ /L	0.188 × [(platelet count ÷ 700) ² – 0.563]	1.0956 when platelet count ≥ 1500 × 10 ⁹ /L
Blood myeloblasts, %	0.0887 × (myeloblasts – 2.10)	0.0584 × myeloblasts
Blood basophils, %	NA	0.20399 when basophils > 3%
Blood eosinophils, %	NA	0.0413 × eosinophils
Relative risk†		
Low	< 0.8	≤ 780
Intermediate	0.8-1.2	781-1480
High	> 1.2	> 1480

Risk according to Sokal et al²⁴ was defined based on patients treated with conventional chemotherapy. Risk according to Hasford et al²⁵ was defined based on patients treated with rIFN α -based regimens. We emphasize that calculation of the risk requires use of clinical and hematologic data at diagnosis, prior to any treatment.

NA indicates not applicable.

*Centimeters below costal margin, maximum distance.

†Relative risk for the Sokal calculation is expressed as exponential of the total; that for the Hasford calculation is expressed as the total × 1000.

from 70% to 25% in the patients who were given transplants in ECP (Table 4).

Progress in molecular DNA typing of HLA alleles, in the management of opportunistic infections, and in supportive care, as well as modifications and improvement of conditioning regimens and immunosuppressive therapy, have contributed to improved results of alloHSCT, using both family members and unrelated donors.⁴³ For patients with CML receiving conventional transplants, the use of peripheral blood stem cells has not been shown to be better than the use of marrow cells.⁴⁴

Reduced intensity conditioning (RIC) is currently being evaluated for CML.⁴⁵⁻⁴⁸ The EBMT has reported on registry data of 187 patients (median age, 50 years) who were submitted to RIC-alloHSCT between 1994 and 2002, mainly from matched-related donors.⁴⁹ Three-year OS was 70% for the patients with an EBMT score of 0 to 2, 50% for the patients with a score of 3 to 4, and about 30% for those with a score of 5 or higher. The use of RIC may permit transplantation also in older patients, but the long-term impact of these and other experimental procedures of alloHSCT on OS, EFS, and quality of life cannot yet be assessed.

The role of treatment intensification with autologous HSCT (autoHSCT) rescue has been the subject of a number of studies and

reviews covering a period of more than 20 years.⁵⁰ Several observations suggested that the procedure was useful in achieving more remissions and prolonging survival. Several randomized studies were initiated but none was completed. A meta-analysis of 6 such trials in which patients were randomly allocated to receive autoHSCT or a rIFN α -based regimen did not show an advantage for autoHSCT.⁵¹

Summary and update of IM data

IM versus rIFN α in ECP

The superiority of 400 mg IM daily over rIFN α and LDAC was established in a prospective randomized international study of 1106 ECP patients (International Randomized Study of Interferon and STI571 [IRIS]). IM was superior to rIFN α for efficacy, with a complete hematologic response (CHR) rate of 95% versus 55%, a CCgR rate of 76% versus 15% and progression-free survival (PFS; survival free from progression to AP/blast crisis [BC]) at 19 months of 97% versus 91% ($P < .001$). It was better also for compliance, toxicity, and quality of life.^{17,52} As expected, molecular response (MoIR) rates were also significantly better, with an estimated major MoIR (MMoIR) rate at 12 months of 40% vs 2%.⁵³ Since many patients who had been assigned to rIFN α and LDAC were crossed over to IM, it is difficult to meaningfully compare the long-term results of the 2 treatment arms. However, 2 independent retrospective analyses provided independent confirmation that IM was better than any other nontransplant treatment.^{54,55} Studies have shown that IM is a cost-effective first-line therapy compared with rIFN α .⁵⁶

Table 3. EBMT transplantation risk score

Prognostic factors	Risk score
Age	
Less than 20 y	0
20-40 y	1
More than 40 y	2
Interval from diagnosis to HSCT	
1 y or less	0
More than 1 y	1
Disease phase	
Chronic	0
Accelerated	1
Blastic	2
Donor-recipient sex match	
Female donor and male recipient	1
Any other match	0
Donor type	
HLA-identical sibling	0
Any other	1

The table lists the prognostic factors and the corresponding risk score as they were calculated in the original EBMT report⁴⁰ and in the subsequent CIBMTR study.⁴¹

Table 4. Overall survival according to EBMT transplantation risk score

Total risk score	5-y overall survival, %		
	EBMT series	CIBMTR series	
		All patients	ECP patients
0-1	72	69	70
2	62	63	67
3	48	44	50
4	40	26	29
5-7	22	11	25

All EBMT and CIBMTR patients were treated by conventional alloHSCT procedures between 1989 and 1997. Leukemia-free survival (calculated only in the EBMT study) at 5 years was 61% for risk scores 0-1, 47% for risk score 2, 37% for risk score 3, 35% for risk score 4, and 19% for risk scores 5-7.

Follow-up clinical results in ECP

When IM was given at 400 mg daily for initial treatment of ECP patients, the CHR rate after 1 year was 95%, and the CCgR rate was 76%.¹⁷ Of those patients who had achieved a CCgR, a MMolR was achieved in 57% (40% of all the patients who had been assigned to IM).⁵³ The proportion of MMolR patients was reported at 55% of all patients after 2 years.⁵⁷ After 54 months of follow-up, PFS was 93%, OS was 90%, and survival freedom from progression to AP/BC as well as from hematologic or cytogenetic relapse was 84%.⁵⁸ Currently, this survival outcome is better than for any other reported treatment. The annual rate of progression to AP/BC appeared to be fairly constant in the first 4 years of treatment, namely 1.5%, 2.8%, 1.6%, and 0.9%.⁵⁸

Clinical results in late chronic phase, AP, and BC

Before IM was initially administered as first-line treatment for CML, it was given to patients who were in CP, but resistant or intolerant to rIFN α , or who had been treated with conventional chemotherapy. These patients are classified as “late CP” (LCP). Four international studies reported a CCgR rate ranging from 41% to 64% with a 5-year PFS of 69% and a 4-year OS of 86% to 88%.^{15,18,19,23,59-61} Moreover, 1 retrospective analysis found that survival of LCP IM-treated patients was superior to that of historical controls, even when a CCgR was not achieved.⁶²

For AP patients the best results were achieved at a daily dose of 600 mg, with a CHR rate of 37%, a CCgR rate of 19%, and a 3-year PFS of 40%.^{17,63} In BC the rate of CHR was about 25%, and several responders also achieved a CCgR, but PFS was short, with a median of 10 months or less, and only 7% remained alive after 3 years.^{5,21-23,63,64}

MolR

Since the frequency of CCgR is very high in IM-treated patients, it is necessary to measure the level of the *BCR-ABL* transcripts to determine minimal residual disease (MRD) (Figure 1). In about 50% of all patients, corresponding to about 70% of the patients who have achieved a CCgR, a substantial reduction, commonly referred




Figure 1. Approximate relationship between response, the putative number of leukemic cells, and the level of *BCR-ABL* transcripts. When a complete cytogenetic response has been achieved, the (putative) number of residual Ph⁺ cells can be measured only with quantitative molecular methods. The figure highlights the importance of molecular methods in the evaluation of the response to treatment. However, the sensitivity of current methods may vary substantially and in any case, no method can detect the transcript at very low cellular levels. For this reason the term “complete molecular response” may be misleading, since it might erroneously be interpreted as an equivalent of complete disease eradication and cure. The term “undetectable *BCR-ABL*” may better describe the biologic situation.

to as a 3-log reduction from a standard baseline or MMolR, was reported in ECP,^{53,65-67} while in LCP the responses were consistently lower.^{19,20,67,68} The actual frequency with which no residual *BCR-ABL* transcripts can be detected by use of the most sensitive available methods, sometimes imprecisely referred to as “complete” MolR (CMolR), is very variable, and ranges from 4% to 34%.^{18,19,57,67,69} The rate at which the *BCR-ABL* transcript levels continue to fall reduces with time.^{57,70,71} This is consistent with the reports that Ph⁺ stem cells may be less sensitive to IM than later Ph⁺ progenitors.⁷²⁻⁷⁵ The question of whether the inability to detect *BCR-ABL* transcripts over the long term is consonant with “cure” cannot yet be answered. Some case reports suggest that the disease may recur shortly after IM discontinuation, so that until more information becomes available IM treatment should not be discontinued without reasons.⁷⁶⁻⁸⁰

Dose issues

The issue of the optimal dose of IM is not yet settled. In early studies for drug registration the maximum tolerated dose was not identified. A dose of 300 mg daily was sufficient to achieve a CHR in almost all LCP patients and at 400 mg daily the blood concentration of IM was consistently higher than that required to inhibit 50% of *BCR-ABL* TK activity in vitro.^{81,82} It was also found that a daily dose of 600 mg was likely to be more effective than 400 mg for AP/BC patients,^{16,21} and that increasing the IM dose to 600 or 800 mg could benefit a subgroup of patients with inadequate response or disease progression.⁸³ Since at higher concentrations IM may inhibit more effectively unmutated *BCR-ABL* and some mutants, studies were initiated to test higher doses also in CP. In patients with both prior hematologic and cytogenetic resistance to 400 mg of IM daily, increasing the IM dose to 800 mg resulted in a CHR in 65% of patients and a CCgR in 18% of patients.⁸⁴ In LCP patients who had not received prior IM, 66% achieved a CCgR.⁸⁵ In ECP patients a CCgR was achieved in 90% of patients, with a 30% CMolR.⁸⁶ In a multicenter Australian study of IM-naïve ECP patients whose dose was escalated from 600 to 800 mg daily, the CCgR rate and the MMolR rate were 81% and 53%, respectively.^{70,87} These studies had no controls and the median follow-up was short (6 to 16 months). Thus, whether increased doses of IM, compared with the standard dose of IM, will achieve an increased overall number of CCgR and MMolR, or whether these effects will merely occur only earlier, remains to be determined. Answers are expected from prospective studies that are in progress.^{13,88,89}

In contrast, no studies have yet explored the response to lower IM doses, probably because the 400 mg dose is usually well tolerated and several reports have discouraged the use of low IM doses because of the possible development of resistance.^{18,19,58,59,66}

Combination with other drugs

Because rIFN α and AC are effective in the treatment of CML, and because their mechanisms of action differ, the combinations of IM with rIFN α and with AC were the first to be tested. In an exploratory study of 77 patients, the combination of 400 mg IM daily with pegylated rIFN α 2b (PegIntron; Schering Plough, Kenilworth, NJ), 50 to 150 μ g weekly, was administered.⁶⁶ The compliance to the combination was limited, since the median tolerated dose of rIFN α was only 35 μ g/week and 50% of patients discontinued rIFN α before the end of the first year of treatment; after 1 year the CCgR and the MMolR rates were 70% and 48%, respectively.⁶⁶ The combination of 400 mg IM with LDAC has been investigated in 30 ECP patients;⁹⁰ at 1 year the CCgR rate was

70%, with grades 3 and 4 hematologic toxicity in 53% of patients. Prospective randomized studies of IM alone versus IM in combination with rIFN α , LDAC, and high-dose AC are ongoing.^{13,89,91}

Several drugs have been shown to overcome IM resistance or to synergize with IM in preclinical models, including leptomyacin B, proteasome inhibitors, mTOR inhibitors, arsenic trioxide, mycophenolic acid, farnesyl-transferase inhibitors, bryostatatin, decitabine, histone-deacetylase inhibitors, homoharringtonine, and phosphoinositol-dependent kinase-1 inhibitors,⁹²⁻¹⁰⁶ but results are still preliminary and limited.¹⁰⁷⁻¹¹⁰

Relationship with alloHSCT

Treatment with IM prior to alloHSCT was not reported to be associated with an increase of transplantation-related morbidity and mortality.¹¹¹⁻¹¹⁵ IM was also found to control leukemia in patients relapsing after alloHSCT.^{116,117} In a multicentric retrospective study of 128 patients, the CCgR rates were 58% in CP, 48% in AP, and 22% in BC, with molecular negativity in 37%, 33%, and 11% of cases, respectively.¹¹⁸ In patients treated in early molecular relapse after alloHSCT, molecular negativity was reinduced in 15/18 cases.⁷⁸ A synergy of IM with donor lymphocyte infusion has been suggested.¹¹⁹

Factors affecting drug concentration in target cells

Several factors can influence IM concentration in target cells, including intestinal absorption, liver metabolism through cytochrome P450 isoenzyme-3A4, plasma binding to α 1-acid-glycoprotein, and the transporters involved in multidrug resistance. P-glycoprotein (Pgp) was found to influence IM intracellular concentration in some studies,¹²⁰⁻¹²⁵ but not in others.^{126,127} Interestingly, some studies have suggested that Pgp inhibition restored IM sensitivity.^{120,124,125} IM does not cross the blood-brain barrier.¹²⁸ Also, the expression of the organic cation transporter hOCT was reported to influence intracellular drug concentration.^{123,129}

Resistance and mutations

Resistance may be multifactorial, including *BCR-ABL* mutations of the kinase domain interfering with IM binding, *BCR-ABL* amplification or overexpression, clonal evolution, and decreased IM bioavailability or cell exposure.^{120,130-141} Clonal evolution and mutations (Table 5) are likely to be the most important factors and are related to each other.^{133,142} The frequency of *BCR-ABL* mutations in resistant patients was reported to range from 42%¹³⁹ to 90%¹³³ depending on the methodology of detection, the definition of resistance, and the phase of the disease. Mutations are found more frequently in AP/BC. In CP patients they are rarer and were identified more frequently in patients with more than 2-fold increase of the *BCR-ABL* transcript levels than in those with stable or decreasing levels.¹⁴³ However, mutant Ph⁺ subclones may remain at low levels, may be transient or unstable, and may not be consistently associated with subsequent relapse.^{144,145} In many cases the mutations have been detected in samples that were collected during IM treatment, but in several cases the mutation was also traced back to samples collected before treatment, especially in cases of AP/BC.^{133,146,147} With more sensitive techniques, mutations were also found in some cases of IM-naive patients and in patients who were in CCgR.¹⁴⁷⁻¹⁴⁹ It is important to note that Ph⁺ primitive cells have been reported to be less sensitive to IM in vitro and in vivo, to harbor *BCR-ABL* mutations even prior to IM exposure, and to develop rapidly mutations under IM pressure.^{72,74,147,149-151} Not all mutations have the same biochemical

Table 5. IC₅₀ values of *BCR-ABL* mutations observed in patients resistant to IM

BCR-ABL	Imatinib IC ₅₀ , nM	
	Biochemical	Cellular
Wild type	300	260-500
M244V	380	2 000
P-loop		
L248V	NA	1 500
G250E	1 000	1 350-3 900
Q252H	NA	1 200-2 800
Y253F	> 5 000	3 475
Y253H*	> 5 000	> 10 000
E255K	2 800	4 400-8 400
E255V	> 5 000	> 5 000
D276G	NA	1 500
T277A	NA	NA
F311L	775	480
F311I	NA	NA
T315I*	> 5 000	> 10 000
F317L*	900	810-1 500
M343T	NA	NA
Catalytic domain		
M351T	820	930
M351V	NA	NA
E355D	NA	NA
E355G	NA	400
F359V*	4 700	1 200
Activation loop		
V379I	800	1 630
A380T*	340	2 450
F382L	NA	NA
L387M	1 500	1 000
L387F	NA	1 100
H396P	340-800	850-4 200
H396R	1 950	1 750
S417Y	NA	NA
E459K	NA	NA
F486S	1 230	2 800

Other mutations not yet detected in patients were recovered from in vitro saturation mutagenesis screenings for mutations conferring resistance to IM or other TK inhibitors. They include M237I, G250A, G250V, E255D, A269V, E281K, E282D, K285N, V289S, V299L, T315A, F317C, V338G, Q346H, S348L, M451L, E352K, E355A, A366D, G398R, G463D, M472I, and E494A, with a cellular IC₅₀ of less than 1460 nM (that is, the mean trough plasma level of IM in patients treated with 400 mg daily); and E255R, E275K, M278L, E279K, E281K, E292Q, Q300H, F311V, T315S, E316D, G321W, D325N, A380S, L384M, M388L, E450K, and E499K, with a cellular IC₅₀ greater than 1460 nM. Data reviewed in Martinelli et al.¹⁵⁴

IC₅₀ indicates the concentration that inhibits by 50% the biochemical TK activity of *BCR-ABL* and suppresses by 50% the growth of Ph⁺ cell lines; NA, not available. *IM contact sites.

and clinical properties (Table 5). The T315I mutation and some mutations affecting the so-called P-loop of *BCR-ABL* confer a greater level of resistance, whereas the biochemical resistance of other mutations can be overcome by a dose increase, and some mutations are functionally irrelevant.^{133,137-140,152-154} Thus, the detection of a kinase domain mutation must be interpreted within the clinical context.

ACAs in Ph⁺ cells (clonal evolution) and OCAs in Ph⁻ cells

Within the Ph⁺ clone additional chromosome abnormalities (ACAs) can be found in a variable proportion of metaphases and in a variable number of patients. This phenomenon, also known and described as clonal evolution, is rare in ECP and becomes more frequent over time and with disease progression.^{23,134,155-160} A negative relationship of ACAs with IM response has been shown, including a lower CgR rate,¹⁵⁷ a higher hematologic relapse rate

(50% vs 9%),¹⁵⁵ and a shorter OS (75% vs 90% at 2 years).¹⁵⁶ Chromosome 9q+ deletions (del9q+) were reported to be associated with less CHR, less CgR, and a shorter PFS in LCP, AP, and BC patients in 1 study¹⁶¹ but not in another.¹⁶²

Other chromosome abnormalities (OCAs) have been reported in the Ph⁻ cells of about 5% of the patients who had achieved a CCgR with IM.¹⁶³⁻¹⁷⁰ Many of these patients were in LCP and had been pretreated with rIFN α -based regimens. OCA included trisomy 8 alone in about 50% of such cases, trisomy 8 with other abnormalities in about 10% of cases, a deletion of chromosome 7 alone or with other abnormalities in about 15% of cases, and other abnormalities in the remaining cases. The balance between the Ph⁺ clone and the Ph⁻ clone with OCAs fluctuated depending on IM treatment, which suppressed Ph⁺ cells and allowed the Ph⁻ clone with OCAs to expand. In some cases Ph⁻ clones with ACAs were reported to be associated with a myelodysplastic syndrome, mainly in patients with a deletion of chromosome 7 and/or other complex abnormalities, but also in patients with isolated trisomy 8. It was also reported that many patients remained in complete cytogenetic and hematologic response after the detection of OCAs and that OCAs may be transient,^{165-167,169,170} but the follow-up is still short.

Prognostic factors

Two sets of prognostic factors can be considered, namely those that can be identified prior to treatment (baseline factors) and those that can be identified during the treatment (response-related factors). The main baseline factors are the phase of disease and the relative risk (RR). Although different definitions of AP and BC have been used (Table 1), the phase of the disease influences strongly the response, the duration of the response, and OS, with better results in CP than in AP and in AP than in BC. The RR, either by the Sokal²⁴ or Hasford methods,²⁵ predicts the cytogenetic response to 400 mg IM daily (Table 6).^{53,171,172} Moreover, the Sokal RR has been reported to predict also MolR and OS. In the IRIS study, the rate of 12-month MMolR among CCgRs was 66%, 45%, and 38% in low-, intermediate-, and high-risk patients, respectively ($P = .007$).⁵³ The OS at 54 months was 94%, 88%, and 81% for low, intermediate, and high Sokal risk patients ($P < .001$).⁵⁸ These risk definitions, which were derived from patients treated with conventional chemotherapy or rIFN α , are still useful, and should be used until further studies identify and confirm other factors of possible prognostic relevance, such as genomic profile,¹⁷³⁻¹⁷⁷ genetic polymorphisms,^{178,179} Wilms tumor gene expression,¹⁸⁰ total phosphotyrosine levels in CD34⁺ cells,¹⁸¹ and the phosphorylation level of the adaptor protein Crkl.¹⁸² In addition, it has been reported that *BCR-ABL* expression levels affect the CgR to IM¹⁹ and determine the rate of development of resistance to IM.¹⁴¹

Table 6. Cytogenetic response by relative risk

Relative risk	Complete cytogenetic response, %		
	Low	Intermediate	High
Italian multicenter study: 77 patients, 400 mg IM, response at 6 mo ¹⁷¹	70	41	8
International multicenter IRIS study: 383 patients, 400 mg IM			
Response at 12 mo ⁵³	76	67	49
Response at 42 mo ¹⁷²	91	84	69
Single-center study: 187 patients, 400-800 mg IM, overall response ⁵⁴	84	85	69

Two independent studies of newly diagnosed patients in ECP who were treated initially with 400 mg IM daily have shown that the cytogenetic and the molecular response to that dose of IM was significantly related to risk according to Sokal et al.²⁴ In 1 study¹⁷¹ the relationship was found also using risk according to Hasford et al.²⁵ In another study⁵⁴ the differences were not significant, but IM dose was higher: 800 mg in 100 patients, 600 mg in 14 patients, and 400 mg in 73 patients. The last update of the IRIS study⁵⁸ reported OS was also risk related: 94% for low-risk patients, 88% for intermediate-risk patients, and 81% for high-risk patients ($P < .001$) after 54 months of therapy.

Table 7. Relationship between the degree of early CgR, the CCgR rate at 2 years, and EFS at 42 months in IRIS study^{172,183}

Time of treatment and cytogenetic response	Probability of CCgR at 2 y, %	EFS at 42 mo, %
3 mo		
Partial	90	NAV
Minor	60	NAV
Minimal/none	50	NAV
6 mo		
Complete/partial	NAP/80	95
Minor or minimal/none	50/15	75
12 mo		
Complete/partial	NAP/50	90
Minor, minimal, or none	< 20	65

From the same study^{172,183} it was reported that after 54 months, survival free from progression to AP/BC was 97% for the patients with a CCgR at 12 months, 95% for those with a partial CgR, and 81% for those who at 12 months had achieved less than a partial CgR.⁵⁸

NAP indicates not applicable, NAV indicates not available.

ACAs, including Ph duplication, and del9q+, are also candidate-adverse prognostic factors.

As data from IRIS study are continuously updated,^{58,172,183} early cytogenetic response seems to be the most important response-related prognostic factor (Table 7). If no CgR is achieved after 3 months, there is still a 50% chance of achieving a CCgR later on. If there is any (even minimal) CgR after 6 months of treatment, there is still a fair chance of achieving a CCgR later on, but if the 6-month karyotype remains more than 95% Ph⁺, the probability is only 15%. After 12 months of treatment, if the CgR is partial the probability of achieving a CCgR at 2 years is still 50%, but if the response is less than partial, this probability becomes less than 20%. The data reported in Table 7 also highlight the relationship between early CCgR and EFS.

The level of MolR was also found to be an important dynamic factor of prognosis. It was reported that transcript levels after 1 or 2 months of treatment predicted late responses,^{184,185} that a low level of residual disease was associated with continuous remission,⁶⁸ and that a MMolR after 12 months of treatment was associated with a better EFS and PFS.^{53,58} A rise of *BCR-ABL* transcript level has been consistently associated with mutations or response loss.^{143,186}

Defining and monitoring the response

HR and CgR

In almost all recent reports on the treatment of CML, HR and CgR were defined virtually the same way, and with only minor

differences.^{15,17-19,26-29,66} We propose to use the definitions that are listed in Table 8. We recommend that HR be evaluated every 2 weeks until a CHR has been achieved and confirmed, and a conventional cytogenetic examination of marrow cells be performed before treatment, at least every 6 months until a CCgR has been achieved and confirmed, then every 12 months. Once an MMolR has been achieved and confirmed, conventional cytogenetic examination of marrow cells may be performed less frequently, depending on clinical, hematologic, and molecular findings.

Fluorescence in situ hybridization (FISH) on interphase cells has the potential advantage of evaluating many more cells and of using peripheral blood instead of marrow,^{187,188} but since the data obtained so far are all based on conventional cytogenetics, we recommend using FISH only before treatment to identify cases of Ph⁻, *BCR-ABL*⁺ CML, and those with variant translocations, Ph amplification, or del9q⁺.

MolR

The necessity for a quantitative definition of MolR has developed with the introduction of IM because with IM, most patients achieve a CCgR, so that molecular methods for measuring MRD are required (Figure 1). The IRIS trial provided evidence for the first time that a reduction of *BCR-ABL* transcripts by 3 or more logs below a standard baseline value correlated with PFS.⁵³ The use of the “log reduction” terminology has led to some degree of confusion since it seems to imply that the value is a relative one. For this reason, at a consensus conference held in Bethesda under the auspices of the National Institutes of Health (NIH), it was proposed to move away from the term “log reduction” and to introduce a standardized numeric International Scale (IS) expressing the amount of *BCR-ABL* as a percentage of a control gene and anchored to 2 “absolute” values based on validated reference materials (plasmids, lyophilised cells or cell extracts) of known value.¹⁸⁹ The first value will be designated 100% on the proposed IS and the second value will represent a 3-log reduction, ie 0.1%. A given laboratory will use the validated reference material to determine the local value that is equivalent to MMolR as determined in the IRIS trial. By comparing the value for a 3-log reduction with the value on the internationally agreed scale, each laboratory can derive a conversion factor which can then be used to express the results in any given patient on the IS.

In ECP patients, evaluating MRD with real-time quantitative polymerase chain reaction (RQ-PCR) does not require bone marrow cells. Blood is drawn (eg, 10 mL), which contains a sufficient amount of leukocytes for RNA extraction from the whole buffy coat. We propose RQ-PCR on peripheral blood cells be

performed at regular intervals of 3 months, even after RQ-PCR becomes negative.

Assessing the molecular status of a patient is not limited to the evaluation of the level of the *BCR-ABL* transcripts. We propose performing a mutational analysis immediately in any case of treatment failure or suboptimal response, including a confirmed rise of *BCR-ABL* transcript level. We recognize, however, that there is currently no consensus regarding the degree of increase which should cause concern,¹⁸⁹ and that there is at present only a limited number of laboratories worldwide currently performing these analyses.

Failure and suboptimal response

The goals of treatment, in order of time and importance, are CHR, CCgR, MMolR, and “complete” molecular response. Although the time to response may not always affect the prognosis, it is operationally useful to define at which timepoint a response may be satisfactory, thus encouraging continuation of current treatment, or if it is not satisfactory, thus requiring or suggesting a change in the therapeutic strategy. Based on the available information, as summarized in prior sections, we propose to define the response to the treatment at different timepoints as “failure” and “suboptimal.” In this context “failure” means that continuing IM treatment at the current dose is no longer appropriate for these patients, who would likely benefit more from other treatments. “Suboptimal response” means that the patient may still have a substantial benefit from continuing IM, but that the long-term outcome of the treatment would not likely be as favorable. Moreover, we propose that some factors should “warn” that standard-dose IM treatment may not be the best choice, and that patients with these factors require a more careful monitoring. The proposed criteria for failure, suboptimal response, and warning are listed in Table 9.

Treatment policy

Standard (noninvestigational) treatment of ECP Ph⁺ CML includes HU, rIFNα ± LDAC, 400 mg IM daily, and alloHSCT. The superiority of IFNα ± LDAC over HU was already demonstrated and confirmed.^{8,30} The superiority of 400 mg IM over IFNα ± LDAC has also been demonstrated.^{17,53} Standard alloHSCT is a recognized therapeutic procedure achieving long-lasting molecular remissions or cures in about 50% of the patients who are eligible for the procedure, with substantial differences among recognized risk groups.^{40,41} In countries where IM is available and standard alloHSCT is feasible, we are now in a rather privileged situation to have 2 potent strategies that are both established but are neither

Table 8. Response definition and monitoring

	Hematologic response	Cytogenetic response	Molecular response (<i>BCR-ABL</i> to control gene ratio according to the international scale)
Definitions	Complete: Platelet count < 450 × 10 ⁹ /L; WBC count < 10 × 10 ⁹ /L; differential without immature granulocytes and with less than 5% basophils; nonpalpable spleen	Complete: Ph ⁺ 0% Partial: Ph ⁺ 1%-35% Minor: Ph ⁺ 36%-65% Minimal: Ph ⁺ 66%-95% None: Ph ⁺ > 95%	“Complete” indicates transcript nonquantifiable and nondetectable Major: ≤ 0.10
Monitoring	Check every 2 wk until complete response achieved and confirmed, then every 3 mo unless otherwise required	Check at least every 6 mo until complete response achieved and confirmed, hence at least every 12 mo	Check every 3 mo; mutational analysis in case of failure, suboptimal response, or transcript level increase

Complete HR, complete CgR, and major MolR should be confirmed on 2 subsequent occasions. CgR is evaluated by morphologic cytogenetics of at least 20 marrow metaphases. FISH of peripheral blood cells should be used only if marrow cells cannot be obtained. MolR is assessed on peripheral blood cells. The international scale for measuring MolR is that proposed by Hughes et al.¹⁸⁹

Table 9. Operational definition of failure and suboptimal response for previously untreated patients in ECP CML who are treated with 400 mg IM daily

Time	Failure	Suboptimal response	Warnings
Diagnosis	NA	NA	High risk, del9q+, ACAs in Ph ⁺ cells
3 mo after diagnosis	No HR (stable disease or disease progression)	Less than CHR	NA
6 mo after diagnosis	Less than CHR, no CgR (Ph ⁺ > 95%)	Less than PCgR (Ph ⁺ > 35%)	NA
12 mo after diagnosis	Less than PCgR (Ph ⁺ > 35%)	Less than CCgR	Less than MMolR
18 mo after diagnosis	Less than CCgR	Less than MMolR	NA
Anytime	Loss of CHR*, loss of CCgR†, mutation‡	ACA in Ph ⁺ cells§, loss of MMolR§, mutation	Any rise in transcript level; other chromosome abnormalities in Ph ⁻ cells

Failure implies that the patient should be moved to other treatments whenever available. Suboptimal response implies that the patient may still have a substantial benefit from continuing IM treatment but that the long-term outcome is not likely to be optimal, so the patient becomes eligible for other treatments. Warnings imply that the patient should be monitored very carefully and may become eligible for other treatments. The same definitions can be used to define the response after IM dose escalation. For risk definitions refer to Table 2. For mutations refer to Table 5. For the definition of HR, CgR, and MolR, refer to Table 8.

PCgR indicates partial CgR; and NA, not applicable.

*To be confirmed on 2 occasions unless associated with progression to AP/BC.

†To be confirmed on 2 occasions, unless associated with CHR loss or progression to AP/BC.

‡High level of insensitivity to IM.

§To be confirmed on 2 occasions, unless associated with CHR or CCgR loss.

||Low level of insensitivity to IM.

perfect nor mutually exclusive. IM is preferred as initial treatment. In a patient with a high disease risk and a low EBMT risk score the choice between IM and alloHSCT should be discussed, but there is little reason to deny such a patient a trial with IM since the early response to IM can either reinforce or weaken the indication for alloHSCT.

The motivations for treatments other than IM are intolerance or excess toxicity, failure, suboptimal response, and “warnings.”

In case of intolerance or excess toxicity, the choices are either alloHSCT or rIFN α \pm LDAC, which must be weighed against investigational trials of new agents and should follow the principle of shared decision-making wherein the patient is informed of the risks and rewards of each treatment decision.

In case of failure (Table 9) we propose that the first choice be alloHSCT or dose-escalation of IM to 600 or 800 mg daily, provided that the patient tolerated 400 mg and that resistance to IM was not associated with a BCR-ABL mutation with a high level of insensitivity to IM.

In case of suboptimal response (Table 9) we propose that the first choice be dose escalation of IM to 600 or 800 mg daily, provided that the patient tolerated 400 mg. AlloHSCT could be offered to patients with a low or intermediate EBMT risk score and high RR or other warning features.

In patients presenting with “warning” features, standard treatment is still 400 mg IM, but any “warning” (Table 9) should alert that the patient might become eligible for IM dose escalation, alloHSCT, or, in selected cases, for investigational agents.

There are several other possible scenarios. The first is the patient in whom other treatment options are not available; in such case the choice would be between continuing IM treatment, if a CHR is maintained, or to resort to HU. The second scenario is the patient requiring IM dose reduction or frequent treatment discontinuations. We recommend that the treating physician advise the patient to adhere to the 400-mg dose insofar as possible; appropriate supportive care should be provided, including myeloid growth factors and erythropoietin; the response should be monitored frequently.

Monitoring of blood IM concentration is not required, but it would be desirable in case of failure, in patients who must take drugs interfering with cytochrome P450, and in those who experience a severe drug-related adverse event.

The proposals and recommendations discussed in this paper focus on ECP patients, but sometimes patients are first diagnosed

when initially in AP or BC. There are few data pertaining to treatment results in these patients. We propose patients in early BC to be treated initially with IM or other TK inhibitors (based on mutational analysis) and then to proceed to alloHSCT. Since some temporal latitude exists after the diagnosis of AP, a more prolonged trial with IM is possible.

Conclusions

Progress in drug development, molecular and cellular biology, and HSCT obliges the medical community to maintain a critical attitude to the management of Ph⁺ CML. On the one hand it must be recognized that the introduction of IM has marked an important and hopefully revolutionary step, but the long-term outcome of this treatment cannot yet be assessed. On the other hand, alloHSCT holds the promise of cure, but with definite toxicity and mortality. At the same time, other TK inhibitors and targeted agents are already in preclinical and clinical evaluation.^{13,154,190-194} The proposals described in this report have been generated by a panel of experts to strike a balance between the magic freedom of research in progress and the practice of advising patients and managing treatment. The proposals concerning treatment policy may be provisional, in the absence of the evidence that will be provided only by longer follow-up of prospective studies; however, the recommendations concerning the methods that must be used to evaluate and to monitor the response are nonetheless cogent. Cytogenetic and molecular monitoring, including mutational analysis, is expensive and requires appropriate resources and sophisticated facilities. However, the cost of monitoring is negligible by comparison with the cost of treatment, whether it is a targeted agent or HSCT. Moreover, careful monitoring is required to ensure that an individual patient receives the proper treatment and to decide if and when a therapy should be changed. Finally, it should be realized that progress makes treatment more effective but not necessarily easier. Thus, the treatment of Ph⁺ CML should be provided under the guidance of an experienced center, offering and asking patients to be registered on investigational studies. This is necessary to ensure that all the data, clinical and biological, that are urgently required to answer the present questions, are collected and analyzed in an accurate and timely

manner, for the benefit of the subsequent patients and for further progress in the treatment of leukemia.

Simona Soverini, PhD, Alessandra Dorigo, Chiara Ferri, and Katia Vecchi is also kindly acknowledged.

Acknowledgments

The scientific contributions of Prof Jörg Hasford and of many members of the European LeukemiaNet, Work Package 4, are acknowledged. The scientific and the technical assistance of

Appendix

The panel identified in the title of this article comprises the authors of this article.

References

- Goldman J. Management of chronic myeloid leukemia. *Semin Hematol* 2003;40:1-103.
- Sawyers CL. Chronic myeloid leukemia. *N Engl J Med*. 1999;340:1330-1340.
- Holyoake TL. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. *Br J Haematol*. 2001;113:11-23.
- Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. *Nat Med*. 1996;2:561-566.
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N Engl J Med*. 2001;344:1031-1037.
- Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *N Engl J Med*. 2001;344:1038-1042.
- Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. *N Engl J Med*. 2002;346:683-693.
- Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. *Blood*. 1999;94:1517-1536.
- Peggs K, Mackinnon S. Imatinib mesylate: the new gold standard for treatment of chronic myeloid leukemia. *N Engl J Med*. 2003;348:1048-1050.
- Bories D, Devergie A, Gardembas M, et al. Stratégies thérapeutiques et recommandations pour la prise en charge des patients atteints de leucémie myéloïde chronique [Treatment strategy and recommendations for patients with chronic myeloid leukemia]. *Hématologie*. 2003;9:497-512.
- Goldman J, Mahon F, Reiffers J. Imatinib for chronic myeloid leukemia. *Semin Hematol*. 2003;40:1-113.
- Stone RM. Optimizing treatment of chronic myeloid leukemia: a rational approach. *Oncologist* 2004;9:259-270.
- Hehlmann R, Berger U, Hochhaus A. Chronic myeloid leukemia: a model for oncology. *Ann Hematol*. 2005;84:487-497.
- Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. *Blood*. 2005;105:2640-2653.
- Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. *N Engl J Med*. 2002;346:645-652.
- Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. *Blood*. 2002;99:1928-1937.
- O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med*. 2003;348:994-1004.
- Kantarjian H, Cortes J, O'Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. *Blood*. 2004;104:1979-1988.
- Rosti G, Martinelli G, Bassi S, et al. Molecular response to imatinib in late chronic phase chronic myeloid leukemia. *Blood*. 2004;103:2284-2290.
- Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
- Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase 2 study. *Blood*. 2002;99:3530-3539.
- Sureda A, Carrasco M, de Miguel M, et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. *Haematologica*. 2003;88:1213-1220.
- Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. *Cancer*. 2005;103:1659-1669.
- Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. *Blood* 1984;63:789-799.
- Hasford J, Pffirmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. *J Natl Cancer Inst*. 1998;90:850-858.
- Hehlmann R, Berger U, Pffirmann M, et al. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. *Leukemia*. 2003;17:1529-1537.
- Baccarani M, Rosti G, de Vivo A, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. *Blood*. 2002;99:1527-1535.
- Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia: French Chronic Myeloid Leukemia Study Group. *N Engl J Med*. 1997;337:223-229.
- Kluin-Nelemans H, Buck G, le Cessie S, et al. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. *Blood*. 2004;103:4408-4415.
- Baccarani M, Russo D, Rosti G, et al. Interferon-alfa for chronic myeloid leukemia. *Semin Hematol*. 2003;40:22-33.
- Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. *Blood*. 2001;98:3074-81.
- Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation. Monitoring treatment and survival in chronic myeloid leukemia. *J Clin Oncol*. 1999;17:1858-1868.
- Simonsson B, Öberg G, Björreman M, et al. Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up. *Acta Haemat*. 2005;113:155-162.
- Gratwohl A, Brand R, Apperley J, et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. *Blood*. 2002;100:3877-3886.
- Robin M, Guardiola P, Devergie A, et al. A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. *Leukemia*. 2005;19:1613-1620.
- Socié G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. *Blood*. 2001;98:3569-3574.
- Goldman JM, Rizzo JD, Jabocinski KA, et al. Long term outcome after allogeneic stem cell transplantation for CML [abstract]. *Hematol J*. 2004;5:98. Abstract no. 266.
- Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long term data and current results: an analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). *Haematologica*. 2006;91:513-521.
- Cwynarski K, Roberts IA, Iacobelli S, et al. Stem cell transplantation for chronic myeloid leukemia in children. *Blood*. 2003;102:1224-1231.
- Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Lancet*. 1998;352:1087-1092.
- Passweg JR, Walker I, Sobocinski KA, et al. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia receiving allogeneic haematopoietic stem cell transplants. *Br J Haematol*. 2004;125:613-620.
- De Souza CA, Vigorito AC, Ruiz MA, et al. Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome. *Haematologica*. 2005;90:232-237.
- Barrett J. Allogeneic stem cell transplantation for chronic myeloid leukemia. *Semin Hematol*. 2003;40:59-71.
- Oehler VG, Radich JP, Storer B, et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. *Biol Blood Marrow Transplant*. 2005;11:85-92.
- Bornhäuser M, Kiehl M, Siegert W, et al. Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. *Br J Haematol*. 2001;115:119-124.
- Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the

- treatment of chronic myeloid leukemia in first chronic phase. *Blood*. 2003;101:441-445.
47. Weisser M, Schleuning M, Ledderose G, et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. *Bone Marrow Transplant*. 2004;34:1083-1038.
 48. Baron F, Maris MB, Storer BE, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. *Biol Blood Marrow Transplant*. 2005;11:272-279.
 49. Crawley C, Szydlo R, Lalancette M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. *Blood*. 2005;106:2969-2976.
 50. Carella AM, Beltrami G, Corsetti MT. Autografting in chronic myeloid leukemia. *Semin Hematol*. 2003;40:72-78.
 51. Richards SM, Apperley J, Carella A, et al. Autografting in chronic myeloid leukaemia: a meta-analysis of six randomized trials [abstract]. *Haematologica*. 2005;90:152-153. Abstract no. 0385.
 52. Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. *J Clin Oncol*. 2003;21:2138-2146.
 53. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. *N Engl J Med*. 2003;349:1421-1432.
 54. Kantarjian H, O'Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. *Cancer*. 2003;98:2636-2642.
 55. Guilhot F, Roy L, Guilhot J, et al. Retrospective comparison of Imatinib versus Interferon plus Cytarabine for chronic myelogenous leukemia patients in chronic phase [abstract]. *Blood*. 2005;106:52a. Abstract no. 165.
 56. Reed SD, Anstrom KJ, Ludmer JA, et al. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. *Cancer*. 2004;101:2574-2583.
 57. Hughes T, Radich J, Kiese B, et al. Long term significance of achieving a major molecular response for first and second line Imatinib treated chronic phase patients with CML entered in the IRIS study [abstract]. *Haematologica*. 2005;90:48. Abstract no. 0118.
 58. Simonsson B, on behalf of the IRIS study group. Beneficial effects of cytogenetic and molecular response on long term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with Imatinib (IM): update from the IRIS study [abstract]. *Blood*. 2005;106:52a. Abstract no. 166.
 59. Kantarjian H, Talpaz M, O'Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. *Clin Cancer Res*. 2002;8:2177-2187.
 60. Cervantes F, Hernández-Boluda JC, Stegmann JL, et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. *Haematologica*. 2003;88:1117-1122.
 61. Gambacorti C, Talpaz M, Sawyers C, et al. Five year follow-up results of a phase II trial in patients with late chronic phase chronic myeloid leukemia treated with Imatinib who are refractory/intolerant of Interferon- α [abstract]. *Blood*. 2005;106:317a. Abstract no. 1089.
 62. Kantarjian H, O'Brien S, Cortes J, et al. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. *Clin Cancer Res*. 2004;10:68-75.
 63. Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase, accelerated phase, or blast crisis chronic myeloid leukemia treated with imatinib in three large phase II trials [abstract]. *Blood*. 2004;104:11a. Abstract no. 23.
 64. Kantarjian H, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. *Blood*. 2002;99:3547-3553.
 65. Müller MC, Gattermann N, Lahaye T, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. *Leukemia*. 2003;17:2392-2400.
 66. Baccarani M, Martinelli G, Rosti G, et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. *Blood*. 2004;104:4245-4251.
 67. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. *Clin Cancer Res*. 2005;11:3425-3432.
 68. Paschka P, Müller MC, Merx K, et al. Molecular monitoring of response to imatinib (Gleevec) in CML patients pretreated with interferon alpha: low levels of residual disease are associated with continuous remission. *Leukemia*. 2003;17:1687-1694.
 69. Mueller MC, Paschka P, Ernst T, et al. Long term surveillance of CML patients on Imatinib therapy: follow-up of German patients treated within the IRIS trial [abstract]. *Haematologica*. 2005;90:153. Abstract no. 0387.
 70. Hughes TP, Branford S, Reynolds J, et al. Maintenance of Imatinib dose intensity in the first six months of therapy for newly diagnosed patients with CML is predictive of molecular response, independent of the ability to increase dose at a later point [abstract]. *Blood*. 2005;106:51a. Abstract no. 164.
 71. Goldman JM, Hughes T, Radich J, et al. Continuing reduction in level of residual disease after 4 years in patients with CML in chronic phase responding to first line Imatinib in the IRIS study [abstract]. *Blood*. 2005;106:51a. Abstract no. 163.
 72. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. *Blood*. 2002;99:319-325.
 73. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. *Blood*. 2003;101:4701-4707.
 74. Elrick LJ, Jorgensen HG, Mountford JC, et al. Punish the parent not the progeny. *Blood*. 2005;105:1862-1866.
 75. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. *Nature*. 2005;435:1267-1270.
 76. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. *Blood*. 2004;104:2204-2205.
 77. Merante S, Orlandi E, Bernasconi P, et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. *Haematologica*. 2005;90:979-981.
 78. Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. *J Clin Oncol*. 2005;23:7583-7593.
 79. Daneschnejad S, Lange T, Mueller C, et al. Imatinib for relapsed Philadelphia chromosome positive chronic myeloid leukaemia after allogeneic haematopoietic cell transplantation [abstract]. *Bone Marrow Transplant*. 2005;35:P800.
 80. Rousselot P, Huguet F, Cayuela JM, et al. Imatinib mesylate discontinuation in patients with chronic myeloid leukaemia in complete molecular remission for more than two years [abstract]. *Blood*. 2005;106:321a. Abstract no. 1101.
 81. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. *J Clin Oncol*. 2004;22:935-942.
 82. Schmidli H, Peng B, Riviere GJ, et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. *Br J Clin Pharmacol*. 2005;60:35-44.
 83. Zonder JA, Pemberton P, Brandt H, et al. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. *Clin Cancer Res*. 2003;9:2092-2097.
 84. Kantarjian H, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. *Blood*. 2003;101:473-475.
 85. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. *Blood*. 2003;102:83-86.
 86. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. *Blood*. 2004;103:2873-2878.
 87. Hughes T, Branford S, Reynolds J, et al. Higher-dose Imatinib (600 mg/day) with selective intensification in newly diagnosed CML patients in chronic phase: cytogenetic response rates at 12 months are superior to IRIS [abstract]. *Blood*. 2004;104:286a. Abstract no. 1001.
 88. Rosti G, Martinelli G, Castagnetti F, et al. Imatinib 800 mg: preliminary results of a phase II trial of the GIMEMA CML working party in intermediate Sokal risk patients and status-of-the-art of an ongoing multinational, prospective randomized trial of Imatinib standard dose (400 mg daily) vs high dose (800 mg daily) in high Sokal risk patients [abstract]. *Blood*. 2005;106:320a. Abstract no. 1098.
 89. Guerci A, Nicolini F, Maloief F, et al. Randomized comparison of Imatinib with Imatinib combination therapies in newly diagnosed chronic myelogenous leukemia patients in chronic phase: design and first interim analysis of a phase II trial from the French CML group [abstract]. *Blood*. 2005;106:53a. Abstract no. 168.
 90. Gardembas M, Rousselot P, Tulliez M, et al. Results of a prospective phase 2 study combining Imatinib Mesylate and Cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. *Blood*. 2003;102:4298-4305.
 91. Cortes J, Talpaz M, O'Brien S, et al. A randomized trial of high dose Imatinib Mesylate with or without Peg-Interferon and GM-CSF as frontline therapy for patients with chronic myeloid leukemia in early chronic phase [abstract]. *Blood*. 2005;106:316a. Abstract no. 1084.
 92. La Rosée P, Johnson K, O'Dwyer ME, et al. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. *Exp Hematol*. 2002;30:729-737.
 93. Hoover RR, Mahon FX, Melo JV, et al. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. *Blood*. 2002;100:1068-1071.
 94. Gatto S, Scappini B, Pham L, et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. *Haematologica*. 2003;88:853-863.

95. Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. *Cancer Res*. 2003;63:5126-5135.
96. La Rosée P, Johnson K, Corbin AS, et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. *Blood*. 2004;103:208-215.
97. Dai Y, Rahmani M, Pei XY, et al. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. *Blood*. 2004;104:509-518.
98. Jørgensen HG, Allan EK, Graham SM, et al. Lonafermin reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. *Leukemia*. 2005;19:1184-1191.
99. Jørgensen HG, Allan EK, Mountford JC, et al. Enhanced CML stem cell elimination in vitro by bryostatins priming with imatinib mesylate. *Exp Hematol*. 2005;33:1140-1146.
100. Tseng PH, Lin HP, Zhu J, et al. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. *Blood*. 2005;105:4021-4027.
101. Aloisi A, Di Gregorio S, Stagno F, et al. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of Imatinib Mesylate and Leptomycin B. *Blood*. 2006;107:1591-1598.
102. Chuah C, Barnes DJ, Kwok M, et al. Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. *Leukemia*. 2005;19:1896-1904.
103. Dengler J, von Bubnoff N, Decker T, et al. Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib. *Leukemia*. 2005;19:1835-1838.
104. Du Y, Wang K, Fang H, et al. Coordination of intrinsic, extrinsic and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. *Blood*. 2006;107:1582-1590.
105. Gu JJ, Santiago L, Mitchell BS. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. *Blood*. 2005;105:3270-3277.
106. Segawa H, Kimura S, Kuroda J, et al. Zoledronate synergizes with imatinib mesylate to inhibit Ph+ primary leukaemic cell growth. *Br J Haematol*. 2005;130:558-560.
107. Cortes J, O'Brien S, Verstovsek S, et al. Phase II study of Lonafermin (SCH66336) in combinations with Imatinib for patients with chronic myeloid leukemia after failure to Imatinib [abstract]. *Blood*. 2004;104:288a. Abstract no. 1009.
108. Cortes J, Garcia-Manero G, O'Brien S, et al. A phase I study of Tipifarnib in combination with Imatinib Mesylate for patients with chronic myeloid leukemia in chronic phase who failed IM therapy [abstract]. *Blood*. 2004;104:289a. Abstract no. 1011.
109. Marin D, Kaeda JS, Andreasson C, et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. *Cancer*. 2005;103:1850-1855.
110. Mauro MJ, Deininger MW, Heinrich MD, et al. Arsenic trioxide (Trisenox) in combination with Imatinib mesylate in patients with Imatinib-resistant chronic myeloid leukemia in chronic phase: results of a phase I/II study [abstract]. *Haematologica*. 2005;90:151-152. Abstract no. 0383.
111. Shimoni A, Kröger N, Zander AR, et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. *Leukemia*. 2003;17:290-297.
112. Kim DW, Chung YJ, Lee S, et al. Pretransplant Imatinib can improve the outcome of non myeloablative stem cell transplantation without increasing the mortality in Philadelphia-chromosome positive chronic myeloid leukemia. *Leukemia*. 2004;18:1907-1909.
113. Zaucha JM, Prejzner W, Giebel S, et al. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. *Bone Marrow Transplant*. 2005;36:417-424.
114. Bornhäuser M, Kröger N, Schwertfeger R, et al. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. *Eur J Haematol*. 2006;76:9-17.
115. Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplant-related mortality. *Haematologica*. 2006;91:452-459.
116. Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. *Blood*. 2002;100:1590-1595.
117. De Angelo DJ, Hochberg EP, Aleya EP, et al. Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. *Clin Cancer Res*. 2004;10:5065-5071.
118. Olavarria E, Ottmann OG, Deininger M, et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. *Leukemia*. 2003;17:1707-1712.
119. Savani BN, Montero A, Kurlander R, et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. *Bone Marrow Transplant*. 2005;36:1009-1015.
120. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. *Blood*. 2000;96:1070-1079.
121. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. *Blood*. 2003;101:2368-2373.
122. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. *Leukemia*. 2004;18:401-408.
123. Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. *Blood*. 2004;104:3739-3745.
124. Radujkovic A, Schad M, Topaly J, et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL: inhibition of P-glycoprotein function by 17-AAG. *Leukemia*. 2005;19:1198-1206.
125. Rumpold H, Wolf AM, Gruenewald K, et al. RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. *Exp Hematol*. 2005;33:767-775.
126. Ferrao PT, Frost MJ, Siah SP, et al. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. *Blood*. 2003;102:4499-4503.
127. Zong Y, Zhou S, Sorrentino BP. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. *Leukemia*. 2005;19:1590-1596.
128. Neville K, Parise RA, Thompson P, et al. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. *Clin Cancer Res*. 2004;10:2525-2529.
129. Crossman LC, Druker BJ, Deininger MW. hOCT 1 and resistance to imatinib. *Blood*. 2005;106:1133-1134.
130. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR-ABL-transformed hematopoietic cell lines. *Blood*. 2000;95:3498-3505.
131. Le Coutre P, Gambacorti-Passerini C. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. *Blood*. 2000;95:1758-1766.
132. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. *Science*. 2001;293:876-880.
133. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. *Cancer Cell*. 2002;2:117-125.
134. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. *Leukemia*. 2002;16:2190-2196.
135. Gambacorti-Passerini C, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. *Lancet Oncol*. 2003;4:75-85.
136. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. *Blood*. 2002;99:3472-3475.
137. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. *Blood*. 2003;102:276-283.
138. Corbin AS, La Rosée P, Stoffregen EP, et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. *Blood*. 2003;101:4611-4614.
139. Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. *Leukemia*. 2004;18:1321-1331.
140. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. *J Clin Oncol*. 2005;23:4100-4109.
141. Barnes DJ, Palaiologou D, Panoussopoulou E, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. *Cancer Res*. 2005;65:8912-8919.
142. Al-Ali HK, Heinrich MC, Lange T, et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. *Hematol J*. 2004;5:55-60.
143. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. *Blood*. 2004;104:2926-2932.
144. Sherbenou DW, Wong MJ, Humayun A, et al. In chronic myeloid leukemia patients with complete cytogenetic response to Imatinib, BCR-ABL kinase domain mutations are relatively rare and not consistently associated with subsequent relapse [abstract]. *Blood*. 2005;106:131a. Abstract no. 434.
145. Khorashad JS, Anand M, Marin D, et al. The presence of a BCR-ABL mutant allele in CML does

- not always explain clinical resistance to imatinib. *Leukemia*. 2006;20:658-663.
146. Roche-Lestienne C, Soenen-Cornu V, Gardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to ST1571, and they can pre-exist to the onset of treatment. *Blood*. 2002;100:1014-1018.
 147. Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naïve patients: correlation with clonal cytogenetic evolution but not response to therapy. *Blood*. 2005;106:2128-2137.
 148. Roche-Lestienne C, Lai JL, Darré S, et al. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. *N Engl J Med*. 2003;348:2265-2266.
 149. Chu S, Xu H, Shah NP, et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. *Blood*. 2005;105:2093-2098.
 150. Angstreich GR, Matsui W, Huff CA, et al. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. *Br J Haematol*. 2005;130:373-381.
 151. Jiang X, Zhao Y, Chan WY, et al. Leukemic stem cells of chronic phase CML patients consistently display very high BCR-ABL transcript levels and reduced responsiveness to Imatinib mesylate in addition to generating a rare subset that produces Imatinib mesylate resistant differentiated progeny [abstract]. *Blood*. 2005;106:204a. Abstract no. 711.
 152. Hochhaus A, Ernst T, Erben P, et al. Long term observation of CML patients after Imatinib resistance associated with BCR-ABL mutations [abstract]. *Blood*. 2005;106:316a. Abstract no. 1086.
 153. Soverini S, Colarossi S, Gnani A, et al. Frequency, distribution and prognostic value of ABL kinase domain mutations in different subsets of Philadelphia-positive patients resistant to Imatinib, by the GIMEMA working party on CML [abstract]. *Blood*. 2005;106:131a. Abstract no. 435.
 154. Martinelli G, Soverini S, Rosti G, et al. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. *Leukemia*. 2005;19:1872-1879.
 155. O'Dwyer M, Mauro MJ, Kurilik G, et al. The impact of clonal evolution on response to imatinib mesylate (ST1571) in accelerated phase CML. *Blood*. 2002;100:1628-1633.
 156. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. *Blood*. 2003;101:3794-3800.
 157. Schoch C, Haferlach T, Kern W, et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. *Leukemia*. 2003;17:461-463.
 158. Mohamed AN, Pemberton P, Zonder J, et al. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. *Clin Cancer Res*. 2003;9:1333-1337.
 159. Markt S, Marin D, Foot N, et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. *Haematologica*. 2003;88:260-267.
 160. O'Dwyer M, Mauro MJ, Blasdel C, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. *Blood*. 2004;103:451-455.
 161. Huntly BJ, Guilhot F, Reid AG, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. *Blood*. 2003;102:2205-2212.
 162. Quintas-Cardama A, Kantarjian H, Talpaz M, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. *Blood*. 2005;105:2281-2286.
 163. O'Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. *Leukemia*. 2003;17:481-487.
 164. Bumm T, Müller C, Al-Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. *Blood*. 2003;101:1941-1949.
 165. Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. *Cancer*. 2003;98:1905-1911.
 166. Abruzzese E, Gozzetti A, Zaccaria A, et al. Ph-abnormal clones emerged during Imatinib therapy: clinical report and clonal analyses on 23 patients from GIMEMA working party in CML registry [abstract]. *Blood*. 2004;104:803a. Abstract no. 2936.
 167. Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. *Leukemia*. 2004;18:1340-1346.
 168. Bacher U, Hochhaus A, Berger U, et al. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. *Leukemia*. 2005;19:460-463.
 169. Deininger MW, Kantarjian H, Byung P, et al. Good prognosis of CML patients with clonal cytogenetic abnormalities in Ph-negative cells [abstract]. *Blood*. 2005;106:315a. Abstract no. 1082.
 170. Jabbour E, Kantarjian H, O'Brien S, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during Imatinib Mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. *Blood*. 2005;106:317a. Abstract no. 1090.
 171. Rosti G, Trabacchi E, Bassi S, et al. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. *Haematologica*. 2003;88:256-259.
 172. Guilhot F, on behalf of the IRIS study group. Sustained durability of responses plus high rates of cytogenetic responses result in long term benefit for newly diagnosed chronic phase chronic myeloid leukemia treated with Imatinib therapy: update from the IRIS study [abstract]. *Blood*. 2004;104:10a. Abstract no. 21.
 173. Tipping AJ, Deininger MW, Goldman JM, et al. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. *Exp Hematol*. 2003;31:1073-1080.
 174. McLean LA, Gathmann I, Capdeville R, et al. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. *Clin Cancer Res*. 2004;10:155-165.
 175. Crossman LC, Mori M, Hsieh YC, et al. In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. *Haematologica*. 2005;90:459-464.
 176. Oehler V, Branford S, Pogossova-Agadjanyan E, et al. Gene expression signatures associated with treatment and resistance to Imatinib mesylate in chronic myeloid leukemia patients. *Blood*. 2005;106:131a. Abstract no. 433.
 177. Yong AS, Szydlo RM, Goldman JM et al. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. *Blood*. 2006;107:205-212.
 178. Dressman MA, Malinowski R, McLean LA, et al. Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (ST1571). *Clin Cancer Res*. 2004;10:2265-2271.
 179. Crossman LC, Loriaux M, Vartanian K, et al. Gene expression profiling of CML CD34+ cells prior to Imatinib therapy reveals differences between patients with and without subsequent complete cytogenetic response [abstract]. *Blood*. 2005;106:330a. Abstract no. 1222.
 180. Cilloni D, Messa F, Gottardi E, et al. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. *Cancer*. 2004;101:979-988.
 181. Schulteis B, Szydlo R, Mahon FX, et al. Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. *Blood*. 2005;105:4893-4894.
 182. White D, Saunders V, Lyons AB, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. *Blood*. 2005;106:2520-2526.
 183. Druker B, Gathmann I, Bolton AE et al. Probability and impact of obtaining a cytogenetic response to Imatinib as initial therapy for chronic myeloid leukemia in chronic phase [abstract]. *Blood*. 2003;102:182a. Abstract no. 634.
 184. Merx K, Müller MC, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. *Leukemia*. 2002;16:1579-1583.
 185. Wang L, Pearson K, Ferguson JE, et al. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. *Br J Haematol*. 2003;120:990-999.
 186. Clark RE, Knight K, Lucas CM, et al. Consecutive but not isolated BCR-ABL transcript level rises are predictive of BCR-ABL kinase mutations in chronic myeloid leukemia patients treated by Imatinib [abstract]. *Exp Hematol*. 2005;33:52. Abstract no. 56.
 187. Lesser ML, Dewald GW, Sison CP, et al. Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia. *Cancer Genet Cytogenet*. 2002;137:79-84.
 188. Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. *Leukemia*. 2002;16:53-59.
 189. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - review and recommendations for "harmonizing" current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. *Blood*. Prepublished online March 7, 2006, as DOI: 10.1182/blood-2006-01-0092.
 190. Shah NP, Tran C, Lee FY, et al. Overriding Imatinib resistance with a novel ABL kinase inhibitor. *Science*. 2004;305:399-401.
 191. Gumireddy K, Baker SJ, Cosenza SC, et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. *Proc Natl Acad Sci U S A*. 2005;102:1992-1997.
 192. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. *Cancer Cell*. 2005;7:129-141.
 193. Golemiovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. *Clin Cancer Res*. 2005;11:4941-4947.
 194. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant ABL kinase domain mutants. *Cancer Res*. 2005;65:4500-4505.